1. Germany Stocks

  2. •

    Healthcare

  3. •

    Medical - Care Facilities
FamiCord AG

FamiCord AG

VTIAF
FamiCord AGUS flagOther OTC
6.38
USD
- -
- -
111.13MMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
4.35
4.42
4.66
5.34
5.41
5
4.86
4.8
4.88
4.36
4.85
4.71
- -
3.98
Basic EPS, GAAP
0.27
0.35
0.65
0.13
-0.09
0.2
0.18
0.35
-0.63
-1.71
-0.12
-0.7
- -
0.07
Free Cash Flow per Basic Share
0.33
0.2
0.65
0.6
0.22
0.93
1.33
0.7
0.08
-0.69
0.32
0.31
- -
-0.03
Dividend per Share
- -
- -
0.15
0.16
0.13
0.16
0.16
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
0.97
0.97
1
1.93
1.68
1.47
0.3
0.66
1.87
-0.92
-0.86
-1.41
- -
-1.85
Tangible Book Value per Share
0.06
0.49
-0.8
-0.47
-2.91
-2.15
-2.36
-1.54
-5.93
-2.67
-2.05
-1.8
- -
-2.47
Basic Weighted Avg Shares
3
3
3
3
4
4
4
4
6
16
16
17
- -
17
Sales/Revenue/Turnover
14
14
14
16
19
20
20
20
28
69
77
82
- -
66
Operating Margin (%)
10.84
10.53
-10.57
4.76
0.7
12.89
12.29
10.04
0.82
-36.06
-3.22
-12.71
- -
3.31
Depreciation Expense
1
1
2
2
2
2
3
3
4
9
9
9
- -
6
Net Income, GAAP
1
1
2
- -
- -
1
1
1
-4
-27
-2
-12
- -
1
Effective Tax Rate (%)
41.33
41.66
- -
10.33
- -
53.36
68.96
22.72
- -
- -
- -
- -
- -
46.03
Profit Margin (%)
6.18
7.98
13.97
2.5
-1.68
4.06
3.72
7.37
-12.9
-39.29
-2.42
-14.77
- -
1.76
Working Capital
4
6
2
3
1
4
4
6
-8
-27
-14
-15
-18
-18
LT Debt
- -
- -
2
- -
7
5
5
3
20
12
14
13
19
19
Total Equity
21
22
24
24
30
30
25
26
42
16
24
13
5
5
Return on Invested Capital (%)
3.89
3.82
- -
2.72
- -
3.29
2.18
4.71
- -
- -
- -
- -
- -
3.79
Return on Capital (%)
21.59
35.37
- -
3.19
- -
6.06
7.56
19.4
- -
- -
- -
- -
- -
-23.82
Return on Common Equity (%)
27.68
36.34
65.38
9.15
-5.45
13.86
20.5
73.57
-53.89
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Jun'25
Sep'25
Dec'25
ST Debt
8
8
5
LT Borrowings
4
3
11
LT Finance Leases
8
8
8
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
17
17
17
Market Capitalization
72
78
91

Working Capital

FRC

•

in mil. unless spec.
Jun'25
Sep'25
Dec'25
Total Current Assets
38
40
39
Cash, Cash Equivalents & STI
12
13
10
Accounts Receivable, Net
16
16
16
Inventories
3
3
3
Total Current Liabilities
58
58
58
Payables & Accruals
- -
- -
- -
ST Debt
8
8
5
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-4.16%
-11.15%
-58.04%
Free Cash Flow
- -
- -
- -
Net Income, GAAP
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
18
18
20
20
77
2024
19
19
22
22
82
2025
22
21
23
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
-0.18
-0.07
-0.1
- -
-0.12
2024
-0.05
-0.09
0.08
- -
-0.7
2025
-0.04
0.04
0.07
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
Jakub Julian Baran
Full Time Employees
783
Sector
Healthcare
Industry
Medical - Care Facilities
Address
Deutscher Platz 5a Leipzig Germany 04103
IPO Date
Feb 18, 2020
Website
vita34.de
Similar Companies
Thai Nakarin Hospital Public Company Limited (TNH.BK)
Mediclinic International plc (MEI.JO)
China Resources Medical Holdings Company Limited (1515.HK)
Option Care Health, Inc. (OPCH)
Twareat Medical Care Co. (9627.SR)
Charming Medical Limited Class A Ordinary Shares (MCTA)
Business
FamiCord AG FamiCord AG (formerly Vita 34 AG) operates as Europe's largest and the world's third-largest stem cell bank, specializing in the collection, processing, cryopreservation, and long-term storage of stem cells from umbilical cord blood, umbilical cord tissue, placenta tissue, and other postnatal tissues; it provides full-service biobanking solutions including logistics, testing, and release for clinical applications, alongside contract development and manufacturing organization (CDMO) services for cell and gene therapies, advanced therapy medicinal products (ATMPs), viral vectors, CAR-T cells, genetic tests, and analyses for third-party biotech firms, clinics, and research institutions. The company serves families and healthcare providers across approximately 50 countries, with key markets in Germany, Poland, Switzerland, Romania, Turkey, the GCC region, Italy, and operations extending to Europe, Asia, and Africa through an extensive network of over 1,500 partner clinics; it has preserved over one million units of biological material and facilitated stem cells for more than 7,000 patient treatments, including over 230 cord blood transplantations. Founded in 1997 and headquartered in Leipzig, Germany, FamiCord AG employs around 766 people and reports segmental revenues primarily from its Vita 34 and PBKM subgroups. In recent developments, FamiCord AG changed its name from Vita 34 AG in February 2025 to reflect the integration of its Vita 34 and PBKM subgroups following their merger; the company completed the acquisition of Seracell Pharma AG, enhancing its stem cell therapy development and ATMP manufacturing capabilities, and acquired BioCell Lugano in Switzerland to expand laboratory infrastructure. Its subsidiary PBKM agreed to acquire 100% of nOvum stem cell bank in Poland in September 2025, while FamiCord AG took a majority stake in Národní Centrum Pupečníkové Krve and Rodinná banka perinatálnych a mezenchymálnych buniek in May 2025 to bolster its Central European presence. Additionally, it rolled out placenta banking services across markets including Switzerland, Poland, Romania, GCC, and Italy, with full expansion targeted by end-2026, and appointed Tomasz Baran as Chief Medical Officer in April 2025 to advance stem cell therapy collaborations with universities and institutions.

Company News

APIChat